I found this 3 hours ago: PPHM was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday. They currently have a $2.30 price target on the stock.
They had really been pumping it too. Pretty much every thing they wrote about any biopharm company would end with a plug for pphm and how much better that is than whatever they were writing about.
Could be monkeys with darts, could be bad news about the fda's reception of the "conservative" attempt to salvage the screwed up data, or just trying to cover both sides so they can have something to look back to and tout their own track record which ever way it goes.
Zacks don`t know jack cause they`re wack,I bought a few stocks off of their recommendations and they either went down or did nothing.So maybe if this is how they play the game we might be staying stagnate for awhile.Zacks does have a tendency to switch gears quick sometimes.To go from outperform to nuetral is a significant change for such a small amount of time.So IMO ,,they could be wrong or jumping the gun to be competitive with the other stock judges.I hope the aren`t hiding info behind the new downgrade.its all fishy to me.
That may be with out any news and untill they can buy it up. This has yet to fully retrace back over 2.75. It will according to how it trades. Accumalating is going on waiting for the next piece of news that moved this over a buck in one day. Stem is in the works for a similar move. I'll hold this one for quite awhile yet.